Timing of Antiretroviral Therapy for HIV-1 Infection and Tuberculosis
Author(s) -
Diane V. Havlir,
Michelle A. Kendall,
Prudence Ive,
Johnstone Kumwenda,
Susan Swindells,
Sarojini S. Qasba,
Anne F. Luetkemeyer,
Evelyn Hogg,
James F. Rooney,
Xingye Wu,
Mina C. Hosseinipour,
Umesh Lalloo,
Valdiléa G. Veloso,
Fatuma Some,
N. Kumarasamy,
Nesri Padayatchi,
Breno Santos,
Stewart E. Reid,
James Hakim,
Lerato Mohapi,
Peter Mugyenyi,
Jorge Sánchez,
Javier R. Lama,
Jean W. Pape,
Alejandro Sanchez,
Aida Asmelash,
E. Moko,
Fred Sawe,
Janet Andersen,
Ian Sanne
Publication year - 2011
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1013607
Subject(s) - medicine , tuberculosis , antiretroviral therapy , immune reconstitution inflammatory syndrome , confidence interval , human immunodeficiency virus (hiv) , immunology , viral load , pathology
Antiretroviral therapy (ART) is indicated during tuberculosis treatment in patients infected with human immunodeficiency virus type 1 (HIV-1), but the timing for the initiation of ART when tuberculosis is diagnosed in patients with various levels of immune compromise is not known.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom